Product Images Levetiracetam

This is a medication bottle label for Levetiracetam tablets USP with a strength of 500mg. The bottle contains 30 tablets and has Lot number T68ty. No other information is available.*

This text is a calculation formula for finding the total daily dose of a medication based on the patient's weight and the daily dose provided in milligrams per kilogram. The medication concentration is given as 100mg/mL.*

This text appears to be explaining a formula for calculating CLer, which is a measure of kidney function in patients. The CLer value is calculated based on the patient's weight, age, and serum creatinine level. The formula is adjusted for body surface area (BSA) to provide a more accurate measurement. However, without additional context or information it is difficult to provide a more detailed description of how this calculation is used in practice.*

This appears to be a table showing the percentages of patients at different levels of treatment for a study involving a placebo group and two different levels of treatment with Levetiracetam at 1000mg/day and 2000mg/day.*

The text represents a table showing the percentage of patients for two groups: Placebo (N=07) and Levetiracetam (N=101). The data is presented in the form of percentages for different categories that are not provided. Some of the categories have missing or unreadable values denoted by the symbol "%". There is no further information available to provide a more specific description of the data presented.*

This text provides the percentage of patients in a study who were given either a placebo or levetiracetam, a medication for seizures. The study consisted of 51 patients who were given a placebo and 58 patients who were given levetiracetam. 19.6% of patients received the placebo and 43.1% received the medication.*

This appears to be a chart or graph displaying the percentage of patients responding to a placebo versus levetiracetam treatment in a clinical trial. The vertical axis shows the percentage of patients in increments of 10 from 0-100%, and the horizontal axis likely shows different time points or dosages. The data shows that the percentage of patients responding to levetiracetam is higher than those responding to placebo across all time points or dosages. Unfortunately, without knowing more about the clinical trial, it is difficult to interpret the results more fully.*